ClinConnect ClinConnect Logo
Search / Trial NCT06495788

Effect of High-intensity Laser Therapy on Patients With Myogenic Temporomandibular Joint Dysfunction

Launched by CAIRO UNIVERSITY · Jul 3, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of high-intensity laser therapy on patients who have myogenic temporomandibular joint dysfunction (TMD). TMD can cause pain in the jaw muscles, specifically the temporalis and masseter muscles, and this study aims to see if laser therapy can help reduce that pain and improve muscle activity.

To participate in the trial, individuals must be between 20 and 45 years old and have been diagnosed with unilateral myogenic TMD, meaning the pain is on one side of the jaw and has lasted for at least three months. Participants should have a moderate level of pain, rated above 3 on a scale of 0 to 10. However, those with certain conditions like previous jaw surgery, specific medical histories, or other complications will not be eligible. The trial is currently not recruiting participants, but it will provide insight into a potential new treatment option for TMD when it begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients from both gender with unilateral myogenic temporomandibular dysfunction (TMD) with trismus diagnosed and referred from maxillofacial specialist.
  • Aged between 20 to 45 years old .
  • Visual analogue scale (VAS) score \>3 for unilateral myogenic pain of the temporomandibular joint (TMJ).
  • Pain lasting at least 3 months.
  • Patients were diagnosed as unilateral myogenic pain.
  • Exclusion Criteria:
  • Previous TMJ surgery.
  • History of jaw dislocation.
  • History of jaw fracture.
  • Previous therapy with occlusal splint.
  • Concomitant therapy of bruxism.
  • Presence of removable oral prosthesis.
  • Metal implants in the skull.
  • Presence of hearing aids.
  • Malignancy.
  • Pregnancy.
  • Diabetic patients.
  • Hypertensive patients.
  • Systemic rheumatologic disease
  • Systemic infection.
  • Inserted cardiac pacemaker.
  • Presence of coagulation disorders.
  • Trigeminal neuritis.
  • Cognitive dysfunction.
  • Bilateral TMD.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Patients applied

0 patients applied

Trial Officials

Amir Saleh, professor

Study Chair

Cairo University

Naglaa Awais, PHD

Study Director

Cairo University

Hala Hazzaa, professor

Study Director

Al-Azhar University

Yasser Lasheen, PHD

Study Director

Cairo University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported